Can we "hedge" against the development of antiviral resistance among pandemic influenza viruses?
Shay
David K
DK
Influenza Division, United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA. david.shay@cdc.hhs.gov
Ridenhour
Benjamin J
BJ
D000998:Antiviral Agents / Q000600:supply & distribution / Q000627:therapeutic use; D004196:Disease Outbreaks / Q000517:prevention & control*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D006291:Health Policy; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects; D009975:Orthomyxoviridae; D009976:Orthomyxoviridae Infections / Q000453:epidemiology / Q000517:prevention & control*; D053139:Oseltamivir / Q000600:supply & distribution / Q000627:therapeutic use
D000998:Antiviral Agents; D053139:Oseltamivir